Bavarian Nordic
Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm. The company has a research and development facility in Martinsried, Germany, and offices in Zug, Switzerland, and Morrisville, North Carolina. The company uses viral vectors in its research and development. Technologies MVA-BN MVA-BN is a proprietary technology developed by Bavarian Nordic. It is derived from the Modified vaccinia Ankara virus. MVA-BN is characterized by the inability to replicate in human cells, contrary to other vaccinia-based vaccines, which may replicate in humans, thus potentially causing severe and life-threatening side effects. Developed as the non-replicating smallpox and monkeypox vaccine, MVA-BN is approved in Canada as Imvamune, in the European Union, as Imvanex, and the United States as Jynneos. The vaccine was supplied for emergency use to the U.S. Strategic National Stockpile as well as other government stockpiles. The vaccine is being deployed worldwide to combat the 2022 monkeypox outbreak, leading to concerns over vaccine nationalism and hoarding by countries with pre-existing contracts. Vaccinia-fowlpox-TRICOM A second poxvirus-based technology is employed